Finanzen von Palvella Therapeutics Inc (PVLA)PVLAPalvella Therapeutics Inc

Evaluating the bottom line, Palvella Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -46.63%, provide a clear picture of how effectively PVLA converts its operational activities into shareholder value.

In the context of the broader market, PVLA competes directly with industry leaders such as AUPH and URGN. With a market capitalization of $2.25B, it holds a significant position in the sector. When comparing efficiency, PVLA's gross margin of N/A stands against AUPH's 92.12% and URGN's 90.93%. Such benchmarking helps identify whether Palvella Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Palvella has a current ratio of 21.18, indicating strong liquidity, but it has consistently reported negative net income, with the latest quarter showing a net loss of -$21.87 million.